hTERT peptide-based vaccine- Invectys

Drug Profile

hTERT peptide-based vaccine- Invectys

Alternative Names: hTERT prptide vaccine- Invectys; Human telomerase reverse transcriptase peptide-based vaccine - Invectys; UCPVax

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Invectys
  • Developer Invectys; Regional and University Hospital of Besancon
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 01 May 2016 Phase-I/II clinical trials in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in France (SC) (NCT02818426)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top